*Dear Editor,*

We were very interested to read the article by Pan and colleagues,[@bib0001] and related letter by Cancella de Abreu[@bib0002] supporting the diagnostic utility of SARS-CoV-2 Lateral Flow Immunochromatographic assays (LFIC) for acute COVID-19 in patients testing negative by RT-PCR at initial screening, provided that serological testing is performed at least one week after symptoms onset. We noted that COVID-19 diagnosis was made on detection of SARS-CoV-2 IgM in the absence of IgG reactivity in a non-negligible fraction of patients in both series (around 50%).[@bib0001] ^,^ [@bib0002] Our experience detailed below casts some doubt on the reliability of an isolated SARS-CoV-2 IgM positive result as determined by LFIC for COVID-19 diagnosis. The current study was approved by the Research Ethics Committee of University Clinic Hospital (HCU), INCLIVA, Valencia (2020-03).

Between March 23 and June 30, 2020 a total of 1,032 patients attended at the emergency department of HCU with clinical suspicion of COVID-19 were tested as per protocol using the ALLTEST 2019-nCoV IgG/IgM Rapid Test Cassette (Hangzhou ALLTEST Biotech Co., Ltd. Hangzhou, China), a LFIC device which detects IgG and IgM against a recombinant SARS-CoV-2 N protein.[@bib0003] The test was carried out and interpreted as recommended in the package insert,[@bib0003] whereby appearance of the test band was recorded as a positive result, irrespective of intensity. According to the manufacturer, the specificity of the SARS-CoV-2 IgM assay is 97.0% (IC95%:86.3%-99.5%).[@bib0003]

The SARS-CoV-2 IgM+/IgG- antibody profile was found in sera from 18 patients (1.7%), which were collected at a median of 7 days (range 5-12 days) after the onset of symptoms (1.7%). Three patients tested positive by RT-PCR in upper respiratory tract (URT) specimens using commercially available RT-PCR assays.[@bib0004] ^,^ [@bib0005] Accordingly, SARS-CoV-2 IgM detected in these 3 patients were deemed to be true positives. The remaining 15 patients (9 females; median age, 67 years; range, 37 to 93 years) tested negative by RT-PCR in URT samples once or several times ([Table 1](#tbl0001){ref-type="table"} ). Follow-up sera from these patients were collected at a median of 11 days (range, 2 to 30 days) after initial serological testing. SARS-CoV-2 IgG seroconversion, which is generally documented by 3-4 weeks after SARS-CoV-2 infection,[@bib0006], [@bib0007], [@bib0008] could not be demonstrated in any cases. Following thorough review of medical charts and based upon clinical, imaging and laboratory findings, repeat negative RT-PCR testing and lack of IgG seroconversion, we came to the conclusion that patients 1,3,4,5,7,9,10,11 and 15 most likely had no COVID-19, whereas patients 2,6,8,12,13 and 14 experienced either possible or probable COVID-19 ([Table 1](#tbl0001){ref-type="table"}). Of note, IgM reactivity persisted in 4 out of 6 follow-up sera from patients categorized as likely having COVID-19 (66.6%), and in 3 out of 9 from patients without it (33.3%).Table 1Characteristics of patients with clinical suspicion of COVID-19 testing IgG-/IgM+ by lateral flow immunochromatography at initial serological screening and negative by RT-PCR in upper respiratory tract specimens.Table 1PatientHospital admission/days of stayNegative RT-PCR results in URTInitial serological testing (days after symptoms onset)LFIC IgM result in initial sera after urea treatment[a](#tb1fn1){ref-type="table-fn"}LFIC result in follow-up seraLFIC result of follow-up sera after urea dissociationFinal diagnosis[b](#tb1fn2){ref-type="table-fn"}1No22-IgG- /IgM-NAUpper respiratory tract infection/No COVID-192No17+IgG- /IgM++Possible COVID-193Yes/1424+IgG- /IgM++Pulmonary abscess secondary to pneumococcal pneumonia4Yes/1337-IgG- /IgM+-Community acquired pneumonia/No COVID-195No310-IgG- /IgM-NAUrinary tract infection due to *Escherichia coli*6Yes/756+IgG- /IgM++Probable COVID7Yes/10210-IgG- /IgM-NAPneumococcal pneumonia8Yes/437+IgG- /IgM++Possible COVID9Yes/8641+IgG- /IgM+-Cardiac insufficiency10Yes/1241-IgG- /IgM-NAHepatic encephalopathy/ ascitic decompensation11Yes/5215-IgG- /IgM-NAPneumococcal pneumonia12Yes/959+IgG- /IgM-NAProbable COVID-1913Yes/7214-IgG- /IgM-NAProbable COVID-1914Yes/1023-IgG- /IgM+-Probable COVID-1915No316-IgG- /IgM-NAFever of unknown origin[^1][^2][^3]

Urea dissociation antibody test performed on LFIC matrices has proven helpful in reducing false-positive IgM results in suspected COVID-19 patients resulting from presence of rheumatoid factor (RF) or other undetermined causes.[@bib0009] ^,^ [@bib0010] SARS-CoV-2 IgM reactivity in initial sera disappeared in 2 out of the 6 patients deemed to have COVID-19 (33.3%) following urea (6M) treatment and in 7 out of 9 patients in whom COVID-19 was judged to be unlikely (78%). Regarding follow-up sera, SARS-CoV-2 IgM were eluted from 1 out 4 sera (25%) from patients with COVID-19 and from 2 out of 3 sera (66.6%) from patients without COVID-19.

We acknowledge that a major limitation of the current study is the potential misclassification of patients as either having COVID-19 or not, which may have occurred due to either a lack of RT-PCR testing of lower tract respiratory specimens, that may yield positive results in the absence of URT SARS-CoV-2 shedding,[@bib0011] or overly prompt follow-up serological testing in patients displaying delayed SARS-CoV-2 IgG seroconversion.[@bib0008] Another drawback of the study is not testing for potential causes of SARS-CoV-IgM false positive reactivity, in particular for presence of RF[@bib0009].

In summary, our data indicate that interpreting the SARS-CoV-2 IgM+/IgG- antibody profile in symptomatic patients with suspected COVID-19, either requiring hospitalization or not, who test negative by RT-PCR is by no means straightforward. In our series, up to 50% of patients displaying that antibody pattern might not have had COVID-19. The prevalence of confirmed COVID-19 cases among patients attended at the emergency department of HCU within the study period was 10-15%. For a SARS-CoV-2 antibody test with a specificity of 97%, such as that of the LFIC used herein, its positive predictive value for COVID-19 diagnosis is expected to be 70-80%, a much higher figure than the one reported herein. Our data also support the assumption that persistent SARS-CoV-2 IgM reactivity in initial or follow-up sera following urea treatment, and repeat positive IgM testing in sequential sera, may both help to reliably establish COVID-19 diagnosis.
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[^1]: LFIC, lateral flow immunochromatographic assay; NA, not applicable; URT, upper respiratory tract.

[^2]: A volume of 10µL of serum was diluted into 1 mL of sample buffer before depositing (100 µL) into the appropriate location of the cassette (Test T-hole). When the fluid was about to reach the absorbent pad, 100 µL of sample buffer containing 6M urea was added to the T hole on the card. Serum specimens were run in parallel in the absence of urea treatment. Each reading was carried out independently by two observers after 20 min incubation.

[^3]: According to the European Centre for Disease Prevention and Control (ECDC) <https://www.ecdc.europa.eu/en/covid-19/surveillance/case-definition>, possible COVID-19 case: any person meeting the clinical criteria; Probable case: any person meeting the clinical criteria with an epidemiological link or person meeting the diagnostic imaging criteria.
